Moxifloxacin Misom Labs (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these enzymes stops bacterial cell division, leading to rapid bacterial death and resolution of the infection.

The dosing regimen for Moxifloxacin Misom Labs is determined by the prescribing clinician based on the type and severity of the ocular infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency and duration of treatment.

Safety data for Moxifloxacin Misom Labs in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against possible risks before prescribing to pregnant or nursing women, and consider alternative treatments when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Moxifloxacin offers broad‑spectrum activity against both Gram‑positive and Gram‑negative ocular pathogens and has a convenient dosing schedule compared with older fluoroquinolones. It is often preferred over agents like ciprofloxacin for its enhanced potency and lower resistance rates, though choice depends on local susceptibility patterns and patient factors.

Store the product at room temperature, preferably below 25 °C, in the original packaging. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the eye drops, and keep the container tightly closed when not in use.

Moxifloxacin Misom Labs is administered as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., twice daily), and the total duration of therapy. Patients should wash their hands before instillation and avoid touching the dropper tip to the eye or any surface.

Serious risks include corneal epithelial toxicity or ulceration, severe allergic reactions such as anaphylaxis, and rare systemic effects like tendon rupture if significant systemic absorption occurs. Patients should seek immediate medical attention if they experience worsening eye pain, vision changes, swelling, or signs of an allergic reaction.

Moxifloxacin Misom Labs should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any excipients in the formulation. Caution is also advised for patients with a history of tendon disorders, severe renal impairment, or those taking systemic fluoroquinolones without medical supervision.